Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.

Sarepta is currently testing SRP-9001 in the placebo-controlled EMBARK study, which aims to enrol 120 boys with DMD aged four to seven and is due to read out in the latter half of 2023.

Cantor Fitzgerald analyst Kristen Kluska upgraded Sarepta (SRPT) to Overweight from Neutral with a price target of $167, up from $152. The company reported Q3 earnings, the first full quarter ...

Rare disease specialist Sarepta Therapeutics has joined with Selecta Biosciences in a research pact to develop ways to allow its gene therapies to be re-dosed. Sarepta is developing gene ...

Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

In June, the FDA expanded its approval of Sarepta Therapeutics’ Elevidys gene therapy for Duchenne muscular dystrophy to all patients ages four and older. The one-time treatment (which costs $3. ...

Guggenheim raised the firm’s price target on Sarepta (SRPT) to $150 from $148 and keeps a Buy rating on the shares. Elevidys and exon-skipping franchise sales were above consensus and management ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the ...

Analyst Luke Sergott of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $209.00. Don't Miss our Black Friday Offers: Luke Sergott has ...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was ...

CAMBRIDGE, Mass., November 06, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2024.